Skip to main content
PLOS One logoLink to PLOS One
. 2023 Apr 12;18(4):e0282396. doi: 10.1371/journal.pone.0282396

Uncomfortably high: Testing reveals inflated THC potency on retail Cannabis labels

Anna L Schwabe 1,¤a,*, Vanessa Johnson 2, Joshua Harrelson 2,¤b, Mitchell E McGlaughlin 1,*
Editor: Lori A Walker3
PMCID: PMC10096267  PMID: 37043421

Abstract

Legal Cannabis products in the United States are required to report THC potency (total THC % by dry weight) on packaging, however concerns have been raised that reported THC potency values are inaccurate. Multiple studies have demonstrated that THC potency is a primary factor in determining pricing for Cannabis flower, so it has an outsized role in the marketplace. Reports of inflated THC potency and “lab shopping” to obtain higher THC potency results have been circulating for some time, but a side-by-side investigation of the reported potency and flower in the package has not previously been conducted. Using HPLC, we analyzed THC potency in 23 samples from 10 dispensaries throughout the Colorado Front Range and compared the results to the THC potency reported on the packaging. Average observed THC potency was 14.98 +/- 2.23%, which is substantially lower than recent reports summarizing dispensary reported THC potency. The average observed THC potency was 23.1% lower than the lowest label reported values and 35.6% lower than the highest label reported values. Overall, ~70% of the samples were more than 15% lower than the THC potency numbers reported on the label, with three samples having only one half of the reported maximum THC potency. Although the exact source of the discrepancies is difficult to determine, a lack of standardized testing protocols, limited regulatory oversight, and financial incentives to market high THC potency likely play a significant role. Given our results it is urgent that steps are taken to increase label accuracy of Cannabis being sold to the public. The lack of accurate reporting of THC potency can have impacts on medical patients controlling dosage, recreational consumers expecting an effect aligned with price, and trust in the industry as a whole. As the legal cannabis market continues to grow, it is essential that the industry moves toward selling products with more accurate labeling.

Introduction

In the U.S., marijuana is a Schedule I controlled substance and is defined as the flowering tops of Cannabis sativa L. containing more than 0.3% total tetrahydrocannabinol (THC) by dry weight [1]. The term “marijuana” has historical negative connotations but there is no alternative agreed upon term for Cannabis types with >0.3% THC [24], so in the current study all references to Cannabis refer to types with >0.3% THC. In recent years attitudes regarding the legal status of Cannabis have shifted substantially at the state level with California being the first U.S. state to allow medical Cannabis use in 1996, and Colorado and Washington both legalizing retail adult use in 2012. As of July 2022, 37 states in the U.S. have passed legislation allowing medical use, 19 of which also allow legal retail adult use [5]. Nationally, Cannabis sales have had significant impacts as evidenced by the almost $10 billion in revenue between 2014 and 2020 in Colorado [6] and record breaking $21.3 billion in national sales in 2020, up 48% from 2019 [7]. Due to the federal status of Cannabis as an illegal substance, individual states have had to take on the challenging task of establishing rules for safely producing, testing, selling, and taxing Cannabis. As a testament to these challenges, the Colorado Department of Public Health & Environment (CDHPE) does not specify a set of clear testing standards and protocols, but instead suggests using in-house validation for testing protocols using “preferred” methods as they become available, and that novel methods need to be rigorously tested and validated prior to use in the analysis of Cannabis product [8].

Female Cannabis flowers have densely packed glandular structures called trichomes that store the phytocannabinoids tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) which must be decarboxylated by heat to produce Δ9-tetrahydrocannabinol (THC: intoxicating) and cannabidiol (CBD: non-intoxicating). Due to both the intoxicating nature and status as a controlled substance, retail and medical Cannabis sold in the legal U.S market requires reporting THC % by dry weight on the product label, either as a range or an average, and may be reported as THC and THCA as separate numbers. The terms “concentration” and “potency” have been used to describe THC % by dry weight; in this work we use potency but recognize that there are many constituents that contribute to the overall effect of a Cannabis product. There are thousands of Cannabis strains and cultivars with unique chemotypes on the legal market that are often categorized as Sativa, Indica, or Hybrid based on purported effects and available ancestry information. These terms are widely used in the industry, by online databases, and by the community, and although the use of these terms is somewhat disputed [911], they will likely continue to be used as part of the common vocabulary for Cannabis products.

The medical and retail cannabis industry encourages the production of strains with high THC, as price is often contingent on THC potency [1215]. Between 1995 and 2012, the THC potency of Cannabis seized by the Drug Enforcement Agency (DEA) increased from an average of ~ 4% to ~12% [16], and additional research confirms THC potency has increased consistently since 1970 [1720]. Cannabis available through the legal market is generally reported to have values greater than 15% THC, and as high as 45% in retail market surveys [21]. Studies examining publicly available data [2123] report higher averages (15%-23.2% THC) than studies conducting independent testing (13.3%-17% THC) [2427]. Recent online media articles addressing THC potency report strains with THC levels ranging from 21–25% THC, with some strains exceeding 30% [2831]. Studies relating to THC potency include assessment of how potency influences price [12, 14, 15], how THC content has increased over time [16, 1820, 32], how cannabinoid profiles vary among samples from different sources [25, 33], and that potency results of the same test material can vary among different testing facilities [3437].

Many reports have questioned the accuracy of Cannabis label data, but limited empirical data exists. A study analyzing sensory perception measured lower than reported THC values from product purchased from two dispensaries in Fort Collins, Colorado (USA) [38], but examining THC potency was not their primary aim. In a recent report, a group of labs in California collaborated to investigate the extent of the THC potency inflation in 150 randomly chosen flower samples [39]. Although not peer-reviewed, the labs found that 87% of samples had label values outside the permissible >10% deviation and over half with >20% deviation of their reported THC potency [39]. Additionally, an audit of Oregon’s testing system in 2019 found that testing may not be reliable and could not ensure safety of the products that were tested, and found some labeled potency results that were substantially higher than the allowable margin of error [40].

The phenomenon referred to as “lab shopping”, where cultivators and dispensaries seek out labs that generate the most desirable lab results, is believed to be problematic in many states [39, 41, 42]. Prices for both medical and retail flower are driven by THC concentration, and Cindy Orser of Digipath labs in Nevada places much of the blame for inaccurate reporting on growers and producers who seek out labs that generate higher numbers [42]. Zoorob found that in both Washington and Nevada there is an unusual statistical spike where many tested strains are reported to be just above 20% THC and noted that the spike was most pronounced in data from two testing labs in Washington that recently had their licenses suspended [43]. Cannabis business owners and consumers have also started to recognize that there is potentially inaccurate commercial THC concentration reporting, with lawsuits filed against companies in Arkansas [44] and California [45] alleging that intentional over-representation of THC concentrations in products has occurred to increase profits. Taken together, these recent studies suggest that there is a substantial amount of THC potency inflation in Cannabis flower for sale in legal markets.

Colorado Department of Revenue (DOR) licensed testing facilities must follow standard operating procedures outlined in the Cannabis Enforcement Division Colorado Cannabis Rules [46], and labeling affixed to the product for sale must include THC and CBD potency values expressed as a percentage of dry weight. According to the rules, potency should be reported as a range from the lowest to the highest percentage from the Test Batch [46]. Preliminary data collected as part of another study found substantial discrepancies between label reported THC percentages and testing data [25] which prompted a deeper investigation into reported label THC concentrations using third-party test results. In this study, we examined Cannabis sourced from across the Colorado Front Range in an attempt to capture a variety of dispensaries with different production protocols and which were presumably using different testing labs to generate the reported THC % dry weight. Sampling was largely opportunistic, including samples collected for other research questions [47] and was intended to provide an overview of label accuracy in Colorado but not to specifically compare dispensaries, cites, or strains. All samples were compared to THC potency results from a single certified third-party Cannabis testing lab. This study was designed from a consumer perspective, with all Cannabis samples purchased directly from dispensaries and THC values reported on the label were assumed to be accurate. Given the growing economic importance, extensive retail and medical consumption, and proposed medical benefits of Cannabis, it is essential that consumers are provided accurate information about the THC potency of Cannabis that they purchase for consumption.

Methods

Sampling

Sampling was focused on obtaining Cannabis flower from a number of Colorado dispensaries to gather general information about the accuracy of THC potency reporting. Samples (n = 23, 1–2 grams per sample) representing 12 strains were purchased from 10 Colorado dispensaries (Table 1). Strains were chosen to represent a diversity of reported proportions of Sativa/Indica (100% Sativa– 100% Indica) and reported THC % by dry weight (lowest: 12.8%—highest: 33.0%; Table 1). Sampling was largely opportunistic within three Colorado cities (Denver, Garden City, and Fort Collins) and included samples collected for other studies [25, 47]. All samples were purchased from Colorado licensed dispensaries, which presumably used several different licensed labs for potency testing, although that information was not available at the point of purchase. Label information was recorded as it was printed on the packaging. Some labels reported a range of THC, and some reported a single number. It was unclear if single values reported were an average of multiple tests, or the result of a single test. Procured samples were stored at—4 °C prior to testing. Flower samples were assigned a random number and taken to a third-party lab (Mile High Labs, Loveland CO) for total THC % by dry weight testing using High Performance Liquid Chromatography (HPLC).

Table 1. Reported and observed THC % by dry weight from Colorado dispensaries.

Strain Name and sample number Dispensary, License # City, ZIP code Reported THC%1 Observed Replicates Observed THC% (Std Dev) % change2
Low High
Colombian Gold ’72 Dispensary 1, 402R-00032 Denver, 80210 19.2 6 12.98 (1.95) -32.40% -
Blue Dream 1 Dispensary 1, 402R-00032 Denver, 80210 17.33–33.00 2 14.91 (0.72) -14.00% -54.80%
Green Crunch (Green Crack) Dispensary 1, 402R-00032 Denver, 80210 12.80–19.30 6 14.90 (0.55)3 16.40% -22.80%
Sour Amnesia Dispensary 1, 402R-00032 Denver, 80210 23.10–26.80 6 15.19 (1.79) -34.20% -43.30%
Mob Boss 1 Dispensary 1, 402R-00032 Denver, 80210 19.00–31.00 3 16.37 (0.23) -13.80% -47.20%
Lemon Skunk Dispensary 1, 402R-00032 Denver, 80210 16.90–17.40 6 17.65 (2.57) 4.40% 1.40%
Afghani Dispensary 2, 402R-00012 Denver, 80210 16.4 6 11.28 (1.08) -31.20% -
Durban Poison 1 Dispensary 2, 402R-00012 Denver, 80210 17.4 3 11.54 (1.38) -33.70% -
OG Kush 2 Dispensary 2, 402R-00012 Denver, 80210 28.07–31.28 2 15.71 (0.27) -49.80% -56.50%
Bubba 98 Dispensary 2, 402R-00012 Denver, 80210 24.38 5 16.40 (3.28) -32.70% -
Durban Poison 4 Dispensary 3, 403R-00073 Denver, 80204 20.88 3 13.72 (2.03) -34.30% -
Gorilla Glue #4 Dispensary 3, 403R-00073 Denver, 80204 25.41–30.88 6 15.68 (0.77) -38.30% -49.20%
Danky Kong Dispensary 3, 403R-00073 Denver, 80204 26.58–27.73 6 19.58 (1.92) -26.30% -29.40%
Blue Dream 4 Dispensary 4, 402R-00340 Denver, 80203 14.41–25.18 3 11.88 (0.53) -17.60% -52.80%
Mob Boss 3 Dispensary 4, 402R-00340 Denver, 80203 22.12–24.87 3 14.32 (0.74) -35.30% -42.40%
Blue Dream 6 Dispensary 5, 402R-00052 Garden City, 80631 26.65–28.23 3 15.17 (1.03) -43.10% -46.30%
Mob Boss 5 Dispensary 5, 402R-00052 Garden City, 80631 25.20–28.90 3 15.54 (0.44) -38.20% -46.20%
Durban Poison 5 Dispensary 6, 402R-00235 Fort Collins, 80524 21.5 3 13.51 (0.57) -37.20% -
OG Kush 3 Dispensary 6, 402R-00235 Fort Collins, 80524 24.2 3 17.86 (0.08) -26.20% -
Blue Dream 5 Dispensary 7, 402R-00220 Fort Collins, 80524 16.64 3 10.47 (0.33) -37.10% -
OG Kush 1 Dispensary 8, 403R-00090 Denver, 80207 15.20–26.14 3 15.76 (0.35) 3 3.70% -39.70%
OG Kush 4 Dispensary 9, 402R-00078 Denver, 80210 15.00–25.01 3 16.68 (0.28) 3 11.20% -33.30%
Blue Dream 3 Dispensary 10, 403R-00596 Denver, 80239 17.87 3 18.22 (0.32) 2.00% -
Mean 20.27–24.10 3.9 14.98 (2.23) -23.1% -35.6% 4

1—Only some dispensaries reported a range of THC % by dry weight, with both the low and high values shown.

2—% Change was calculated as observed THC % dry weight relative to either the lowest or highest reported value. All values that had more than a 15% change are bolded.

3—Observed THC % by dry weight fell within the reported range.

4—Mean included the low value when only a single value was reported

THC testing

Mile High Labs analyzed the samples following standard protocols with a gradient 1260 Infinity II HPLC with DAD detection at 240 nm, (bandwidth 4 nm) and reference 360 nm (bandwidth 100 nm) using a reverse-phase column and guard column with a C18 stationary phase. Cerilliant © Certified Cannabinoid Standards (Redrock, Texas) were used to measure THC and THCA concentrations. Total THC was calculated using the industry standard equation THCTOTAL = THC + (THCA x 0.877) which determines total THC when THCA and THC are separated during chromatography [46]. All HPLC settings and standards met Colorado state compliance requirements. The dried, homogenized samples were analyzed in three successive HPLC replicates. Additionally, eight samples were analyzed a second time, each with three successive replicates, to test for consistency of the HPLC testing protocol (S1 Table).

Statistical analyses

Percent change of THC potency was calculated as:

%change=observerdpotencyreportedpotencyreportedpotency*100%

Percentage change was calculated for both low and high reported THC values when a range was reported on the Cannabis packaging. Statistical analyses were conducted using IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, N.Y., USA). An Independent Samples T-test was used to compare the eight samples that were analyzed twice. Due to the differences in the number of samples within our two groups, Reported THC and Observed THC, the non-parametric Wilcoxon Signed Rank Test was used to compare differences between groups. For this analysis only the lowest Reported Label THC value was used.

Results

Twenty-three Cannabis samples representing 12 strains (Table 1) were analyzed. For two samples (Blue Dream 1 and OG Kush 2) one HPLC replicate was excluded from analyses due to poor data. No significant difference was found between the eight samples analyzed in two separate HPLC replicates (Independent Samples T-test, p = 0.240). The Wilcoxon Signed Rank Test, which was conducted using only the first HPLC run for the eight samples that were tested twice, found that there was a significant difference between reported and observed THC % by dry weight (Z = 3.833; p < 0.001; Fig 1). Eighteen of 23 samples (78.26%) had a lower observed THC % by dry weight than the lowest value reported on the label, with an observed average of 14.98% and reported average value of 20.27% and 24.10% for low and high label ranges, respectively (Table 1, Fig 2). Sixteen of 23 samples (69.56%) had observed values that were more than 15% lower relative to the lowest reported THC % by dry weight, and 13 of those samples (56.52%) were more than 30% lower than the reported value. When examining the highest reported value, 20 of 23 samples (86.95%) had observed values that were more than 15% lower relative to the highest reported THC %, with 18 of those samples (78.26%) that were more than 30% lower. A single sample, Green Crunch (Green Crack), had an observed value higher than 15% relative to the lowest reported THC % by dry weight, but the label for this sample reported a range that the observed value fell within. Over all samples, the observed THC % by dry weight was 23.1% lower than the lowest reported values and 35.6% lower than the highest reported value.

Fig 1. Box and whisker plot.

Fig 1

Mean THC % by dry weight for observed (light blue) and reported values (dark blue).

Fig 2. Mean THC % by dry weight for observed vs. reported values.

Fig 2

Each Cannabis sample is indicated along the x-axis, and error bars show the standard deviation. Samples are grouped by the dispensary they were purchased from. For samples with a reported range of THC % by dry weight, the mean of those values is presented. Reported values with no error bar were sold with a single number for THC % by dry weight.

Discussion

Our results demonstrate that there are substantial, statistically significant differences between THC % by dry weight (hereafter THC potency) reported on consumer labels and our observed test results (Table 1, Figs 1 and 2). On average, observed THC potency was 23.1% lower than the lowest label reported values and 35.6% lower than the highest label reported values, with a maximum percentage change of -56.5%. Furthermore, 13 of 23 tested samples (~57%) had observed values that were more than 30% lower than the lowest reported value, while only seven samples (~30%) were within 15% of the lowest reported THC potency. Dispensaries with two or more samples had at least one sample where the observed THC potency was more than 34% lower than the lowest label reported value (Table 1). Although we recognize that this study includes a relatively small number of samples, this in no way impacts the empirical test results of those samples, and our sampling included a diversity of dispensaries and strains to provide a board overview of the current state of THC potency reporting along the Colorado Front Range. This is the first peer-reviewed study to empirically examine commercial THC potency; however, there are multiple recent investigative reports from the Cannabis industry that support our finding of significant overreporting of THC potency [48, 49], suggesting that overreporting is an industry wide issue. Given that increased THC and CBD potency are associated with higher prices [1215], and that potency and price are the major factors driving sales [42, 50], comparisons relative to the highest reported potency are likely more indicative of what consumers expect when making purchasing decisions. These results make clear that consumers are often purchasing Cannabis that has a much lower THC potency than is advertised and that this occurrence is widespread across the Colorado Front Range.

Information disclosed to the public about THC potency in the legal Cannabis marketplace is limited to numbers reported on the label at the point of sale, and some online databases. Dispensaries may also print a QR code on the label which can be scanned to retrieve the Certificate of Analysis (COA) lab report detailing cannabinoid and other tests performed on the batch the sample came from. However, raw data and testing methods are not often included on packaging or in COA reports. Recent published studies report retail THC potency ranging from ~15–23.2% [2125], while online articles reference strains with THC potency ranging from 21–25%, with some strains with >30% THC potency [2831]. Vergara et al. [23] found differences in average THC levels among states, which may indicate different testing methods, but may also reflect regional consumer preferences. An investigative study conducted in 2011 tested six samples at ten different labs and found the testing results deviated substantially for each of the samples [51]. ElSohly et al. [18] evaluated 14,234 samples of Cannabis from 2009 to 2019 and the results showed the mean THC potency had increased from 9.75% in 2009 to 13.88% in 2019, which is in line with our observed average of 14.98%, as opposed to the average THC potency advertised online for medicinal (19.2% ±6.2) and retail (21.5% ±6.0) products [21].

Although our study was not designed to pinpoint the source of THC potency discrepancies, we have outlined four areas that are likely to be important based on Colorado regulations.

  1. Sample Collection–It has been documented that THC potency varies in flowers located on the top, middle and lower branches on the plant as well as the timing of plant development [52]. Colorado has developed guidelines for how flowers should be sampled [53], but there is limited to no enforcement of these guidelines. If growers are not randomly selecting flowers from throughout plants for testing, THC potency results may not be indicative of the entire batch [52].

  2. Sample Testing—Although testing facilities are licensed through the DOR and standard operating procedures have been outlined by the Cannabis Enforcement Division Colorado Cannabis Rules [45], there are multiple variables that could lead to different results. Of note, Colorado standard operating procedures allow for differences in sample preparation, usage of different internal standards, and usage of different analytical instruments, all of which could impact THC potency measurements. The testing instrumentation used in this study is the most common method used in Colorado, with all ten current testing labs advertising HPLC as the method to quantify the THC % by dry weight of cannabinoids tested in each sample. Therefore, the methodology used in this study should not impact the observed decrease in THC content of samples.

  3. Sample Degradation–THC is known to degrade if not stored correctly. Ross and ElSohly [54] found that when stored at room temperature THC potency decreased by 16.6% (±7.4) after one year, and up to 41.4% (±6.5) after four years. Furthermore, when exposed to light at room temperature, THC is almost 100% degraded after four years [55]. However, when THC degrades, it is converted to cannabinol (CBN) which was not observed in sizeable quantities in the samples used in this study, indicating the lower potency in the observed versus reported values were not due to age or poor storage conditions.

  4. Economic Incentive–Consumers often make purchasing decisions based on THC potency and are willing to pay more for higher potency flower [12, 50, 56]. This creates incentive for retailers and testing facilities to report the highest possible THC potency, which could be inflated by manipulating flower sampling, analytical procedures, or reported data. The research by Zoorob (2021) clearly illustrates that reported THC potency test results in Nevada and Washington show an unusually high frequency of products with potency just above 20% [43]. Additionally, media outlets have released reports of testing labs in multiple states (California, Colorado, Oregon, Washington, and Nevada) that had misrepresented potency values [5759].

It is currently unclear how many consumers are aware of issues with THC potency reporting and how it might impact their purchasing decisions. Our work only examined flower material but given the financial incentives to report high THC potency it is likely that inflated potency is common for all THC containing products. Accurate label reporting is essential to ensure consumer trust. If consumers find they cannot trust THC potency reporting, they may also question the reliability of other testing results, such as a lack of pesticides, molds, and other contaminants [60].

Based on our results, there are several areas where THC potency testing and reporting could be improved. In Colorado, Cannabis flower sold on the legal market is required to be tested for total THC potency by a licensed testing facility that is reported as a range on the label [45]. Only 61.9% of our samples had a reported range of THC potency and in most samples that range was much higher than our observed values. This suggests that both flower harvesting protocols and reporting rules need to be enhanced to ensure commercial samples fall within the reported range. Independent testing should be implemented to compare THC potency values at time of harvest and point of sale to determine if THC potency is changing throughout the processing and sale. Finally, rigorous standard operating procedures should be developed to minimize testing variation among labs.

Conclusion

As Cannabis becomes more widely used in retail and medicinal contexts, it is important that consumers are presented with accurate information about the THC potency of what they are consuming. Our results clearly demonstrate that retail Cannabis flower THC potency is significantly inflated in samples purchased in Colorado. Given the numerous recent reports and lawsuits questioning THC potency reporting, it is likely that this is an industry wide problem. Additional studies should be conducted in other states and with larger sample sizes to confirm our findings. Although we have no power to change the current system, we hope highlighting this issue and educating consumers will affect the change needed to remedy inflated potency of flower products. Addressing this discrepancy will require both changes to the regulatory system and consumer awareness that reported THC potencies are frequently inflated.

Supporting information

S1 Table. Raw data from HPLC testing conducted by Mile High Labs.

(PDF)

Acknowledgments

We would like to thank Laura Heiker for consulting on regulatory and compliance for Colorado testing procedures, Emily Holt and Scott Franklin for aiding with the statistical methods, and Gabriella Mueller and Cheysser Harding for arranging the HPLC testing.

Data Availability

All data is in the supplementary table.

Funding Statement

Headspace Sensory LLC provided funding for purchase of 13 of the 23 Cannabis samples that were included as part of another study [47], but had no other involvement in this study. All other funding was provided by the McGlaughlin Lab at the University of Northern Colorado and by the first author. Mile High Labs provided support for this study in the form of salaries for VJ and JH. The specific roles of these authors are articulated in the ‘author contributions’ section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

Decision Letter 0

Lori A Walker

14 Jul 2022

PONE-D-22-13833

Uncomfortably High: Testing Reveals Inflated THC Potency on Retail Cannabis Labels

PLOS ONE

Dear Dr. McGlaughlin,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

  • The abstract should be more detailed and the introduction should include appropriate references of similar studies that have already been published.

  • De-identification of the dispensaries from which product for testing was obtained unless the authors are able to establish consent from the stated dispensaries.

  • Expended details on testing methods both by the authors and the methods used by the dispensaries, highlighting any differences.

  • Sample size justification

It is also suggested that the term recreational cannabis be changed to non-medical use of cannabis.

Please submit your revised manuscript by Aug 28 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Lori A. Walker

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

   "Acknowledgments: We would like to thank Laura Heiker for consulting us on regulatory and compliance for Colorado testing procedures, Emily Holt and Scott Franklin for aiding with the statistical methods, Gabriella Mueller and Cheysser Harding for arranging the HPLC testing, and Avery Gilbert for providing some of the funding to purchase samples

Funding: Funding was provided by the University of Northern Colorado Graduate Student Association, the McGlaughlin Lab at the University of Northern Colorado, the first author and Headspace Sensory LLC."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

 "The authors received no specific funding for this work"

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a thoughtful paper that is well written. My only comment is that the implications for public health policy should be drawn out more fully in the discussion. What does this mean for keeping consumers in a potentially "safer" regulated and legal market? While accurate THC potency is a quality control issue, is is also a consumer trust issue and I think there would be concerns (beyond profit motives) about losing people to an illicit market? Finally, while this paper addresses flower product I think it requires some thought about implications for shatter and dabs - the products typically associated with the highest THC potency. Overall, great paper! I think it will have an impact.

Reviewer #2: The issue described in this manuscript, specifically the listed potency of delta-9 THC products commercially and their actual potency, is an important question and standardized testing or regulations around testing have not been formalized. While this is an important topic to study, the gaps in the literature are not well articulated given that other studies have analyzed commercially available products and have demonstrated discrepancies in listed vs. actual values.

There has been an emphasis on referring to recreational cannabis use as non-medical use (as compared to medical use). The authors may consider use of these terms in their manuscript.

Is including the names of dispensaries appropriate? It seems that the information should be coded to maintain confidentiality, even though these were purchased legally by investigators. Given that samples were purchased there without dispensaries consenting to research, can the authors state the ethical conduct of this study and approval by the institution?

How does the testing of product completed as part of this study compare to how dispensaries may be testing product? The specifics of testing among sampled dispensaries is not listed, but some general sense of how these tests are normally being conducted would be helpful.

The justification for 23 samples is not provided and no justification is provided for the number selected from each city and from each dispensary.

Since samples varied across cities and dispensaries, were there relationships between accuracy across those variables? Would it be the case that certain dispensaries, given their testing standards, would be more accurate than others, or does strain play a role in this?

Minor comments:

The abstract is very short and additional information could be included. I believe PLOS One has an abstract word count of 300 words, so details could be expanded on this study. In expanding the information in the abstract, abbreviations should also be defined upon first use.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Apr 12;18(4):e0282396. doi: 10.1371/journal.pone.0282396.r002

Author response to Decision Letter 0


17 Aug 2022

Please see the response to reviewers with information related to editor and reviewer comments.

Academic Editor Comments

• The abstract should be more detailed and the introduction should include appropriate references of similar studies that have already been published.

- We have substantially expanded the abstract to add more background and context to our findings. We have also added more background to introduction, particularly related to previous THC potency studies (particularly LN 88-114), and expanded our literature cited throughout the manuscript.

• De-identification of the dispensaries from which product for testing was obtained unless the authors are able to establish consent from the stated dispensaries.

- All dispensary information has been de-identified.

• Expended details on testing methods both by the authors and the methods used by the dispensaries, highlighting any differences.

- We have provided additional context on how our HPLC methods relate to the testing labs our conducting. As we have now clarified, we used the method that is advertised by all current testing facilities in the state of Colorado (LN 261-265) and our analytical methods were developed based on State of Colorado testing guidelines (LN 159-160).

• Sample size justification

- We have provided more context on our sampling detailing that it was largely opportunistic (LN 126-128, 141-142). This study came about when we were collecting data for a sensory project and we discovered that there was a large discrepancy between reported and observed potency. Based on this unexpected result we validated our methods by retesting 8 samples, as detailed in the methods, and expanded our sampling as resources allowed. Although our sample size is relatively small, that in no way impacts the result that there is substantial over-reporting of potency occurring in the marketplace (LN 222-225).

It is also suggested that the term recreational cannabis be changed to non-medical use of cannabis.

- We do not like the term ‘non-medical use’, but we have replaced all references to ‘recreational’ to ‘retail” as referred to by the Colorado Department of Revenue Cannabis Enforcement Division.

Reviewer 1 Comments

Reviewer #1: This is a thoughtful paper that is well written. My only comment is that the implications for public health policy should be drawn out more fully in the discussion. What does this mean for keeping consumers in a potentially "safer" regulated and legal market? While accurate THC potency is a quality control issue, is is also a consumer trust issue and I think there would be concerns (beyond profit motives) about losing people to an illicit market?

- We have added more context related to public health in the discussion specifically addressing public trust (LN 282-288).

Finally, while this paper addresses flower product I think it requires some thought about implications for shatter and dabs - the products typically associated with the highest THC potency.

- Although the question of accuracy related to reported potency for extracts and concentrates is of interest, it is outside the scope of the current work. We did suggest that additional THC containing products should be tested in a similar study (LN 283-285) and included reference to one review paper that summarizes what is known about label accuracy for other products (LN 288).

Reviewer 2 Comments

Reviewer #2: The issue described in this manuscript, specifically the listed potency of delta-9 THC products commercially and their actual potency, is an important question and standardized testing or regulations around testing have not been formalized. While this is an important topic to study, the gaps in the literature are not well articulated given that other studies have analyzed commercially available products and have demonstrated discrepancies in listed vs. actual values

- We have expanded our introduction to cover more recent publications related to listed vs. actual potency values (LN 88-98) and reports of “lab shopping” (LN 100-114). However, this continues to be an understudied area with very limited studies that have collected empirical data.

It seems that the information should be coded to maintain confidentiality, even though these were purchased legally by investigators. Given that samples were purchased there without dispensaries consenting to research, can the authors state the ethical conduct of this study and approval by the institution?

- All dispensaries have been de-identified.

How does the testing of product completed as part of this study compare to how dispensaries may be testing product? The specifics of testing among sampled dispensaries is not listed, but some general sense of how these tests are normally being conducted would be helpful.

- We have expanded our description of how testing is normally done in Colorado and that HPLC is the most common method (LN 261-265).

The justification for 23 samples is not provided and no justification is provided for the number selected from each city and from each dispensary.

- We have provided more context on our sampling detailing that it was largely opportunistic (LN 126-128, 141-142). This study came about when we were collecting data for a sensory project and we discovered that there was a large discrepancy between reported and observed potency. Based on this unexpected result we validated our methods by retesting 8 samples, as detailed in the methods, and expanded our sampling as resources allowed. Although our sample size is relatively small, that in no way impacts the result that there is substantial over-reporting of potency occurring in the marketplace (LN 222-225). We have also reorganized Table 1 and Figure 2 so samples are grouped by dispensary and discussed that the observed discrepancies occurred for all dispensaries with 2 or more samples in the dataset (LN 220-222).

Attachment

Submitted filename: Response_to_Reviewers.docx

Decision Letter 1

Lori A Walker

3 Nov 2022

PONE-D-22-13833R1

Uncomfortably High: Testing Reveals Inflated THC Potency on Retail Cannabis Labels

PLOS ONE

Dear Dr. McGlaughlin,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised as noted below.

Please submit your revised manuscript by Dec 18 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Lori A. Walker

Academic Editor

PLOS ONE

***Request from Staff Editors***

In the interest of reproducibility and to ensure that your submission meets our third publication criterion https://journals.plos.org/plosone/s/criteria-for-publication#loc-3 please address the following points noted below:

  • We understand that you purchased cannabis from local dispensaries for this study. In your Methods section, please provide additional details regarding the source of this material assayed. For instance, if available, please provide the geographic coordinates and/or names of the purchase locations/dispensaries (e.g., stores, markets), as well as any further details about the purchased items (e.g., lot number, source origin, description of appearance).

 

  • In addition, please provide further details about the criteria used to select the dispensaries from which to assay samples.

 

  • Lastly please consider expanding on the limitations of the study, including on the generalisability of the findings for all retail Cannabis labels as inferred from the title of this work.

 

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

********** 

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

********** 

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

********** 

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No

Reviewer #3: Yes

********** 

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

********** 

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Revisions are satisfactory and I recommend acceptance. Data availability is unclear though in the statement provided by the authors and should be clarified per journal requirements.

Reviewer #3: The manuscript is well written, the data are of public and scientific interest, the results interpretation is balanced and on point.

Consider adding some comments that THC concentrations could also have a different meaning depending on the potential CBD presence, concentration, and ratio.

********** 

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Apr 12;18(4):e0282396. doi: 10.1371/journal.pone.0282396.r004

Author response to Decision Letter 1


6 Dec 2022

December 6, 2022

Dear Dr. Walker,

Thank you for the recent reviews on our manuscript PONE-D-22-13833R1, Uncomfortably High: Testing Reveals Inflated THC Potency on Retail Cannabis Labels. We have responded to all of the staff editor and reviewer comments, as detailed below, and submitted an updated version of the manuscript with and without track changes. Overall, we feel that the manuscript is ready for publication. If you have any questions or concerns, feel free to contact us.

Sincerely,

Mitchell McGlaughlin and Anna Schwabe

• We understand that you purchased cannabis from local dispensaries for this study. In your Methods section, please provide additional details regarding the source of this material assayed. For instance, if available, please provide the geographic coordinates and/or names of the purchase locations/dispensaries (e.g., stores, markets), as well as any further details about the purchased items (e.g., lot number, source origin, description of appearance).

To address this comment, we did two things.

1) We added dispensary license numbers and zip codes to Table 1 (Ln 225). As we previously communicated to the editorial staff (but never received a response), we do not want to list dispensaries by name because our goal was not single out ‘good’ or ‘bad’ dispensaries, rather we wanted to show that there are THC potency reporting issues across many producers. Removing dispensary names was also requested by a reviewer during the review process. We feel that the details in Table 1 now strike the appropriate balance between our goals and documenting where sampling occurred.

2) We reworked our sampling details in the methods (Ln-151-158). Since we were looking at broad patterns there was not a specific sampling strategy beyond having samples with a diversity of Sativa/Indica proportions and reported THC concentrations (ln 154-155).

We do not feel that descriptions of the material, beyond that we purchased flower, is necessary. This is particularly relevant since we approached this study via a consumer perspective. Other sample details, including lot # or source, are incredibly inconsistent from producers, making them not informative. These reporting issues are highlighted throughout our manuscript and in multiple cited studies within.

• In addition, please provide further details about the criteria used to select the dispensaries from which to assay samples.

Addressed relative to the previous requested edit. Our sampling strategy is addressed in the introduction (Ln 121-126) and methods (Ln 136-137, 141-145).

• Lastly please consider expanding on the limitations of the study, including on the generalisability of the findings for all retail Cannabis labels as inferred from the title of this work.

We previously had content that addressed our sample size limitations (Ln 244-247). In this version we have expanded upon that discussion (Ln 248-251) providing additional citations that support that our findings are consistent with what is occurring across the industry. We also added additional text to the introduction (Ln 108-112) to include a second lawsuit related to inflated THC potency and then adjusted our conclusions section (Ln 340-343) to make clear that our results are specific to samples in Colorado and to recommend further research including more samples from other states.

Reviewer Comments

Reviewer #2: Revisions are satisfactory and I recommend acceptance. Data availability is unclear though in the statement provided by the authors and should be clarified per journal requirements.

All of our data is available in supplementary Table S1 as stated on Ln 575 and uploaded into the manuscript system.

Reviewer #3: The manuscript is well written, the data are of public and scientific interest, the results interpretation is balanced and on point.

Consider adding some comments that THC concentrations could also have a different meaning depending on the potential CBD presence, concentration, and ratio.

This request is outside the scope of our manuscript. The reviewer is absolutely correct that there are different effects and descriptions based on combinations of different cannabinoids. This is an active area of study within the field, which is best approached with different methods and study design. All samples included in this study were high THC drug-type samples available at recreational Cannabis dispensaries. We make clear that we are looking solely at THC % throughout the introduction based on the importance of THC % to regulation/defining drug-type Cannabis (Ln 43-44) and the importance it plays in marketing and pricing Cannabis (Ln 74-112).

Attachment

Submitted filename: Response_to_Reviewers_R2.docx

Decision Letter 2

Lori A Walker

15 Feb 2023

Uncomfortably High: Testing Reveals Inflated THC Potency on Retail Cannabis Labels

PONE-D-22-13833R2

Dear Dr. McGlaughlin,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Lori A. Walker

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Lori A Walker

16 Mar 2023

PONE-D-22-13833R2

Uncomfortably High: Testing Reveals Inflated THC Potency on Retail Cannabis Labels

Dear Dr. McGlaughlin:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Lori A. Walker

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Raw data from HPLC testing conducted by Mile High Labs.

    (PDF)

    Attachment

    Submitted filename: Response_to_Reviewers.docx

    Attachment

    Submitted filename: Response_to_Reviewers_R2.docx

    Data Availability Statement

    All data is in the supplementary table.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES